IBDEI0QE ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,12978,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,12978,1,1,0)
 ;;=1^200.10
 ;;^UTILITY(U,$J,358.3,12978,1,2,0)
 ;;=2^LYMPHOSARCOMA
 ;;^UTILITY(U,$J,358.3,12978,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,12979,0)
 ;;=172.9^^78^810^36
 ;;^UTILITY(U,$J,358.3,12979,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,12979,1,1,0)
 ;;=1^172.9
 ;;^UTILITY(U,$J,358.3,12979,1,2,0)
 ;;=2^MALIGNANT MELANOMA
 ;;^UTILITY(U,$J,358.3,12979,2)
 ;;=^75462
 ;;^UTILITY(U,$J,358.3,12980,0)
 ;;=199.0^^78^810^39
 ;;^UTILITY(U,$J,358.3,12980,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,12980,1,1,0)
 ;;=1^199.0
 ;;^UTILITY(U,$J,358.3,12980,1,2,0)
 ;;=2^METASTATIC CA OF UNKN PRIMARY
 ;;^UTILITY(U,$J,358.3,12980,2)
 ;;=^267340
 ;;^UTILITY(U,$J,358.3,12981,0)
 ;;=203.00^^78^810^40
 ;;^UTILITY(U,$J,358.3,12981,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,12981,1,1,0)
 ;;=1^203.00
 ;;^UTILITY(U,$J,358.3,12981,1,2,0)
 ;;=2^MULTIPLE MYELOMA
 ;;^UTILITY(U,$J,358.3,12981,2)
 ;;=^336847
 ;;^UTILITY(U,$J,358.3,12982,0)
 ;;=238.75^^78^810^41
 ;;^UTILITY(U,$J,358.3,12982,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,12982,1,1,0)
 ;;=1^238.75
 ;;^UTILITY(U,$J,358.3,12982,1,2,0)
 ;;=2^MYELODYSPLASTIC SYNDROME
 ;;^UTILITY(U,$J,358.3,12982,2)
 ;;=^334031
 ;;^UTILITY(U,$J,358.3,12983,0)
 ;;=157.9^^78^810^43
 ;;^UTILITY(U,$J,358.3,12983,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,12983,1,1,0)
 ;;=1^157.9
 ;;^UTILITY(U,$J,358.3,12983,1,2,0)
 ;;=2^PANCREATIC CANCER
 ;;^UTILITY(U,$J,358.3,12983,2)
 ;;=^267103
 ;;^UTILITY(U,$J,358.3,12984,0)
 ;;=187.9^^78^810^44
 ;;^UTILITY(U,$J,358.3,12984,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,12984,1,1,0)
 ;;=1^187.9
 ;;^UTILITY(U,$J,358.3,12984,1,2,0)
 ;;=2^PENILE CANCER
 ;;^UTILITY(U,$J,358.3,12984,2)
 ;;=^267252
 ;;^UTILITY(U,$J,358.3,12985,0)
 ;;=163.9^^78^810^46
 ;;^UTILITY(U,$J,358.3,12985,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,12985,1,1,0)
 ;;=1^163.9
 ;;^UTILITY(U,$J,358.3,12985,1,2,0)
 ;;=2^PLEURAL CANCER
 ;;^UTILITY(U,$J,358.3,12985,2)
 ;;=^267140
 ;;^UTILITY(U,$J,358.3,12986,0)
 ;;=185.^^78^810^47
 ;;^UTILITY(U,$J,358.3,12986,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,12986,1,1,0)
 ;;=1^185.
 ;;^UTILITY(U,$J,358.3,12986,1,2,0)
 ;;=2^PROSTATE CANCER
 ;;^UTILITY(U,$J,358.3,12986,2)
 ;;=^99481
 ;;^UTILITY(U,$J,358.3,12987,0)
 ;;=287.9^^78^810^48
 ;;^UTILITY(U,$J,358.3,12987,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,12987,1,1,0)
 ;;=1^287.9
 ;;^UTILITY(U,$J,358.3,12987,1,2,0)
 ;;=2^PURPURA/OTH HEMORRHAGIC COND
 ;;^UTILITY(U,$J,358.3,12987,2)
 ;;=^123920
 ;;^UTILITY(U,$J,358.3,12988,0)
 ;;=154.3^^78^810^49
 ;;^UTILITY(U,$J,358.3,12988,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,12988,1,1,0)
 ;;=1^154.3
 ;;^UTILITY(U,$J,358.3,12988,1,2,0)
 ;;=2^RECTAL CANCER
 ;;^UTILITY(U,$J,358.3,12988,2)
 ;;=^267092
 ;;^UTILITY(U,$J,358.3,12989,0)
 ;;=189.9^^78^810^64
 ;;^UTILITY(U,$J,358.3,12989,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,12989,1,1,0)
 ;;=1^189.9
 ;;^UTILITY(U,$J,358.3,12989,1,2,0)
 ;;=2^URINARY ORGAN CANCER
 ;;^UTILITY(U,$J,358.3,12989,2)
 ;;=^267269
 ;;^UTILITY(U,$J,358.3,12990,0)
 ;;=142.9^^78^810^51
 ;;^UTILITY(U,$J,358.3,12990,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,12990,1,1,0)
 ;;=1^142.9
 ;;^UTILITY(U,$J,358.3,12990,1,2,0)
 ;;=2^SALIVARY GLAND CANCER
 ;;^UTILITY(U,$J,358.3,12990,2)
 ;;=^267009
 ;;^UTILITY(U,$J,358.3,12991,0)
 ;;=160.9^^78^810^54
 ;;^UTILITY(U,$J,358.3,12991,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,12991,1,1,0)
 ;;=1^160.9
 ;;^UTILITY(U,$J,358.3,12991,1,2,0)
 ;;=2^SINUS,NASAL & MIDDLE EAR CANCER
 ;;^UTILITY(U,$J,358.3,12991,2)
 ;;=^267127
